6 recruiting, 5 active not recruiting, 3 completed, 1 terminated. 8 Phase 1, 4 Phase 2, 3 Not applicable, 1 Phase 3.
Follow Locally Advanced Lung Non-Small Cell Carcinoma: new trials by email Literature Review of Locally Advanced Lung Non-Small Cell Carcinoma trials Research Report on Locally Advanced Lung Non-Small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 37 | 2026-06-17 | 2026-09-04 |
| Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS) Locally Advanced Lung Non-Small Cell Carcinoma | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 150 | 2024-03-29 | 2024-04-15 | |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer Carboplatin, Cisplatin, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 474 | 2023-07-12 | 2026-08-17 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer Biopsy, Osimertinib, Triptolide Analog - Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 8 | 2022-03-07 | 2026-03-05 |
| ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy Cisplatin, Durvalumab, Etoposide - Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 2 | Terminated | University of Washington | 1 | 2021-12-10 | 2023-06-13 |
| Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel - Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 28 | 2021-12-06 | 2026-06-30 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Not applicable | Recruiting | M.D. Anderson Cancer Center | 100 | 2021-07-05 | 2026-09-16 |
| Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer Computed Tomography, Contrast Agent - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Not applicable | Active not recruiting | Rutgers, The State University of New Jersey | 34 | 2021-02-11 | 2026-06-11 |
| Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC Bevacizumab, Brigatinib - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 5 | 2020-03-09 | 2026-07-01 |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2019-10-28 | 2025-09-23 |
| Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Ipilimumab, Nivolumab, Radiation Therapy - ALK Gene Rearrangement, EGFR Gene Mutation | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 21 | 2019-09-13 | 2026-09-14 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer Antiretroviral Therapy, Biopsy, Biospecimen Collection - AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Completed | National Cancer Institute (NCI) | 58 | 2016-04-04 | 2024-08-09 |
| Stereotactic Ablative Radiotherapy in Locally Advanced Non Small Cell Lung Cancer Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer - Locally Advanced Lung Non-Small Cell Carcinoma | Not applicable | Completed | Radiotherapy Oncology Centre "Santa Maria" Hospital | 80 | 2015-12-01 | 2022-03-23 |
Lung Neoplasms (13) · Carcinoma, Non-Small-Cell Lung (7) · Melanoma (3) · Carcinoma, Hepatocellular (2) · Neoplasm Metastasis (2) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Cardiotoxicity (1) · Endometrial Neoplasms (1) · HIV Infections (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1)
Lung Diseases (13) · Neoplasms by Site (13) · Respiratory Tract Diseases (13) · Respiratory Tract Neoplasms (13) · Thoracic Neoplasms (13) · Neoplasms (12) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Pathologic Processes (3)
Immunoglobulin G (7) · Disulfides (6) · Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · Biopsy (4) · durvalumab (4) · Contrast Media (3) · Pemetrexed (3) · Radiation (3) · Radiotherapy (3) · X-Rays (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · CTLA-4 Antigen (2) · Carboplatin (2) · Cisplatin (2)
M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · City of Hope Medical Center (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Mayo Clinic (1) · NRG Oncology (1) · Ohio State University Comprehensive Cancer Center (1) · Radiotherapy Oncology Centre "Santa Maria" Hospital (1) · Rutgers, The State University of New Jersey (1) · University of Washington (1)
United States (13) · Italy (2) · Canada (1)
Andreas N Saltos (1) · Anne S Tsao (1) · Charles B Simone (1) · Erminia Massarelli (1) · Ernesto Maranzano, MD (1) · Fabio Arcidiacono, MD (1) · Fabio Trippa, MD (1) · Jeremey Brownstein, MD (1) · Jing Zeng (1) · Kathryn Lurain (1) · Michelina Casale, PhD (1) · Paola Anselmo, MD (1) · Rodabe Amaria, MD (1) · Salma K Jabbour, MD (1) · Steven H Lin (1)
PMID 10661362, PMID 18718891, PMID 19403881, PMID 20351327, PMID 20393019, PMID 22454424, PMID 24011407, PMID 25450876, PMID 25601342, PMID 25746732, PMID 25846093, PMID 25957184, PMID 27013408, PMID 27189322, PMID 28109804, PMID 28210143, PMID 30095228, PMID 30496842, PMID 30943123, PMID 31154457, PMID 32275994, PMID 32822540, PMID 33476803, PMID 35080914, PMID 35537412, PMID 36288758, PMID 37328287, PMID 39356983, PMID 39615497, PMID 41680482
U10CA180868 (2), P30CA015704 (1), P30CA033572 (1), P30CA060553 (1), P30CA072720 (1), R01CA262388 (1), R01HL157273 (1), U01CA154967 (1), UM1CA186644 (1)